Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.4% - Here's What Happened

Key Points

• Rapport Therapeutics shares fell 7.4% to about $27.21 despite positive Phase 2 results, with trading volume roughly 69% below its average.
• The company said RAP-219 met the primary and secondary endpoints in bipolar mania and plans to advance the drug into Phase 3 trials, though some coverage called the results modest and suggested profit-taking.
• Analysts remained broadly bullish, with BTIG and Raymond James raising price targets to $89 and $86, respectively; the consensus rating is “Buy” with a $67 target price.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report)'s stock price dropped 7.4% on Wednesday. The company traded as low as $27.82 and last traded at $27.2110. Approximately 121,229 shares changed hands during trading, a decline of 69% from the average daily volume of 391,842 shares. The stock had previously closed at $29.37.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: Rapport reported that its Phase 2 trial of RAP-219 met both the primary and secondary endpoints. At Week 3, the treatment produced a statistically significant placebo-adjusted 3.1-point improvement in the Young Mania Rating Scale and a 0.4-point improvement in the Clinical Global Impression–Bipolar severity score. Rapport Phase 2 topline results
• Positive Sentiment: The company plans to advance RAP-219 into Phase 3 bipolar-mania trials, reducing some development uncertainty and supporting the potential for a larger commercial opportunity. Rapport plans Phase III trials
• Positive Sentiment: Analysts responded favorably: BTIG raised its price target to $89 from $75, Raymond James increased its target to $86 from $75, and HC Wainwright reaffirmed a Buy rating with a $66 target. Analysts have cited a potential blockbuster opportunity, with estimated peak sales near $1 billion. Raymond James price target increase
• Neutral Sentiment: Investor reaction has been volatile, with unusually heavy trading volume following the data release as the market weighs the clinical results and the transition toward Phase 3. Rapport trading volume
• Negative Sentiment: Some coverage characterized the trial win as modest because RAP-219 fell short of the study’s original ambitions, which may explain profit-taking and the stock’s continued weakness despite positive headline results. Rapport Phase 2 analysis

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. BTIG Research boosted their price objective on shares of Rapport Therapeutics from $75.00 to $89.00 and gave the company a "buy" rating in a research note on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a research report on Thursday, October 15th. Guggenheim lifted their target price on Rapport Therapeutics from $65.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $66.00 target price on shares of Rapport Therapeutics in a report on Tuesday. Finally, Raymond James Financial restated a "strong-buy" rating and set a $86.00 price target on shares of Rapport Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $67.00.

Rapport Therapeutics Stock Down 10.8%

The firm's 50 day moving average price is $40.31 and its two-hundred day moving average price is $39.13. The firm has a market capitalization of $1.26 billion, a PE ratio of -8.62 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). On average, sell-side analysts anticipate that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Abraham Ceesay sold 1,147 shares of the company's stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $30.66, for a total transaction of $35,167.02. Following the completion of the transaction, the chief executive officer directly owned 452,245 shares in the company, valued at $13,865,831.70. This represents a 0.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Cheryl Gault sold 10,000 shares of the company's stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $33.19, for a total transaction of $331,900.00. Following the transaction, the chief operating officer owned 139,914 shares of the company's stock, valued at $4,643,745.66. This represents a 6.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 97,976 shares of company stock worth $4,420,349 over the last quarter. Insiders own 12.48% of the company's stock.

Institutional Trading of Rapport Therapeutics

A number of large investors have recently modified their holdings of the company. Algert Global LLC acquired a new position in Rapport Therapeutics during the 2nd quarter valued at about $9,327,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $74,360,823. Legal & General Group Plc acquired a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $940,000. Walleye Capital LLC bought a new stake in shares of Rapport Therapeutics during the second quarter valued at approximately $4,257,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Rapport Therapeutics during the second quarter valued at approximately $3,426,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.